ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up

A. A. Vo1, N. Ammerman1, E. Huang1, M. Toyoda2, S. Ge2, A. Peng1, R. Najjar1, S. Williamson1, C. Meyers1, S. Sethi1, K. Lim1, J. Choi1, S. C. Jordan1

1Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, 2Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: 573

Keywords: B cells, Highly-sensitized, Kidney transplantation, Rejection

Session Information

Session Name: Kidney Immunosuppression: Desensitization

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report a 12M follow-up of this single center Phase I/II study to assess safety & efficacy of Clazakizumab (anti-IL-6, Vitaeris) for DES in highly-HLA sensitized (HS) patients.

*Methods: Ten HS patients (cPRA >50%) received PLEX x5 followed by IVIg 2gm/kg X1. Post-IVIg, patients received anti-IL-6 25mg SC Q4W X6 with monitoring of HLA antibody and other immune parameters. Study end point was transplantation by day 270 post-Rx. Transplanted patients received claza 25mg SC Q4W. After protocol biopsy at 6M, patients continued claza for 12M post-transplant. The primary end point was reduction of HLA antibodies from baseline. All transplanted patients received induction with alemtuzumab and maintained on tac/mmf/pred.

*Results: Nine patients were transplanted. Briefly, mean time from dialysis to transplant was 96±52M and from last claza to transplant was 5.5±3.6M. All patients had previous transplants; 78% had cPRA 99-100%, 67% were B-cell FCMX+ and CII DSA+ @transplant. Mean MFI for HLA CI & CII were: pre-des v. post claza: CI 13062±3123 v. 8585±4597 (p=0.05) and CII 13519±2966 v. 8344±4836 (p=0.03). Figure 1 showed DSA MFI pre & post-tx to month 12. No patients had detectable DSA @6M post-tx. Protocol biopsies @6M in 8 patients (89%) showed mean g+ptc: 0.75±1.9, cg: 0.375±0.99, c4d: 0.625±1.1, ci+ct: 1.25±1.4, and i-IFTA: 0.75±1.1 respectively (Figure 2). Two patients developed rejection CMR/ABMR and cABMR as a result of DSA rebound. Mean eGFR @12M was 51±26 ml/min.

*Conclusions: Overall, there was a significant reduction in HLA MFI for CI and CII post-claza in 9/10 patients. No patient had detectable DSA 6M post-transplant. Therefore, anti-IL-6 appears promising as a desensitization agent when used with PLEX + IVIg. Anti-IL-6 also reduced antibody rebound post-PLEX + IVIg likely allowing successful HLAi transplantation for these patients.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Vo AA, Ammerman N, Huang E, Toyoda M, Ge S, Peng A, Najjar R, Williamson S, Meyers C, Sethi S, Lim K, Choi J, Jordan SC. Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-the-safety-and-tolerability-of-clazakizumab-as-a-desensitization-agent-in-highly-hla-sensitized-esrd-patients-nct03380962-12m-follow-up/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences